Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial.
Abstract
One hundred eighty patients were randomly assigned. CR was achieved in 40 (43%) patients on ruxolitinib versus 23 (26%) on BAT (odds ratio, 2.12; 90% CI, 1.25 to 3.60; P = .02). Duration of CR was superior for ruxolitinib (hazard ratio [HR], 0.38; 95% CI, 0.24 to 0.61; P < .001). Symptom responses were better with ruxolitinib and durable. EFS (major thrombosis, hemorrhage, transformation, and death) was superior for patients attaining CR within 1 year (HR, 0.41; 95% CI, 0.21 to 0.78; P = .01); and those on ruxolitinib (HR, 0.58; 95% CI, 0.35 to 0.94; P = .03). Serial analysis of JAK2V617F variant allele fraction revealed molecular response was more frequent with ruxolitinib and was associated with improved outcomes (progression-free survival [PFS] P = .001, EFS P = .001, overall survival P = .01) and clearance of JAK2V617F stem/progenitor cells. ASXL1 mutations predicted for adverse EFS (HR, 3.02; 95% CI, 1.47 to 6.17; P = .003). The safety profile of ruxolitinib was as previously reported.
Author
Harrison, Claire N
Nangalia, Jyoti
Boucher, Rebecca
Jackson, Aimee
Yap, Christina
O'Sullivan, Jennifer
Fox, Sonia
Ailts, Isaak
Dueck, Amylou C
Geyer, Holly L
Mesa, Ruben A
Dunn, William G
Nadezhdin, Eugene
Curto-Garcia, Natalia
Green, Anna
Wilkins, Bridget
Coppell, Jason
Laurie, John
Garg, Mamta
Ewing, Joanne
Knapper, Steven
Crowe, Josephine
Chen, Frederick
Koutsavlis, Ioannis
Godfrey, Anna
Arami, Siamak
Drummond, Mark
Byrne, Jennifer
Clark, Fiona
Mead-Harvey, Carolyn
Baxter, Elizabeth Joanna
McMullin, Mary Frances
Mead, Adam J
Nangalia, Jyoti
Boucher, Rebecca
Jackson, Aimee
Yap, Christina
O'Sullivan, Jennifer
Fox, Sonia
Ailts, Isaak
Dueck, Amylou C
Geyer, Holly L
Mesa, Ruben A
Dunn, William G
Nadezhdin, Eugene
Curto-Garcia, Natalia
Green, Anna
Wilkins, Bridget
Coppell, Jason
Laurie, John
Garg, Mamta
Ewing, Joanne
Knapper, Steven
Crowe, Josephine
Chen, Frederick
Koutsavlis, Ioannis
Godfrey, Anna
Arami, Siamak
Drummond, Mark
Byrne, Jennifer
Clark, Fiona
Mead-Harvey, Carolyn
Baxter, Elizabeth Joanna
McMullin, Mary Frances
Mead, Adam J
Citations
Altmetric:
Date
2023-05-01
Type
Article
Subject
Haematology, Oncology. Pathology., Pharmacology, Practice of medicine
Citation
Harrison CN, Nangalia J, Boucher R, Jackson A, Yap C, O'Sullivan J, Fox S, Ailts I, Dueck AC, Geyer HL, Mesa RA, Dunn WG, Nadezhdin E, Curto-Garcia N, Green A, Wilkins B, Coppell J, Laurie J, Garg M, Ewing J, Knapper S, Crowe J, Chen F, Koutsavlis I, Godfrey A, Arami S, Drummond M, Byrne J, Clark F, Mead-Harvey C, Baxter EJ, McMullin MF, Mead AJ. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. J Clin Oncol. 2023 Jul 1;41(19):3534-3544. doi: 10.1200/JCO.22.01935. Epub 2023 May 1.
Journal / Source Title
Journal of Clinical Oncology
DOI
10.1200/JCO.22.01935
PMID
37126762
Publisher
American Society of Clinical Oncology
Publisher’s URL
https://ascopubs.org/loi/jco
https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=toc&D=yrovft&AN=00005083-000000000-00000
https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=toc&D=yrovft&AN=00005083-000000000-00000